A Phase 4 interventional study of voriconazole and anidulafungin in Aspergillosis, sponsored by Pfizer. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-15.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.
Among the 17 studies testing voriconazole in Aspergillosis, this one is the 15th largest by enrollment, is one of 3 that started in 2008, is one of 4 in phase 4, and was the 7th registered.
134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.
Browse Aspergillosis studies →None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →
Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 4
First in 1997; this study’s year is marked. 3 started in 2008.
This study's enrollment of 6 is below the median of 47 across 75 interventional studies indexed under Aspergillosis.
Median enrollment 24 across the 17 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
11 studies in Aspergillosis by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Aspergillosis by Pfizer, this one is one of 3 that started in 2008, is one of 3 in phase 4, and was the 4th registered.
Pfizer’s Aspergillosis studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing voriconazole in Aspergillosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 11 in Aspergillosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.
The study was terminated on January 12, 2009 due to the overall low rate of enrollment. The decision to terminate the trial was not based on any safety concerns. Patients who were enrolled in the study prior to January 12, 2009 were allowed to remain in the study until completing their participation as specified in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy.
Exclusion Criteria:
Patients with invasive aspergillosis for more than 30 days at the time of study entry. Patients with uncontrolled bacterial or viral infection at the time of study entry. Patients with significant liver dysfunction or who are taking certain medications which interact with voriconazole.
anidulafungin plus voriconazole
Drug: voriconazole
anidulafungin plus voriconazole
Drug: anidulafungin
Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
Also known as: Vfend
Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
Also known as: Eraxis
Summary of Global Response at End of Treatment (EOT)
Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.
Time frame: End of Treatment (Day 42)
Summary of Global Response at Week 2, Week 4, and Week 6
Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.
Time frame: Week 2, Week 4, Week 6
Summary of Mortality
Number of subects with documented mortality (death).
Time frame: Up to Week 6
Galactomannan Titer Assay Levels and Global Response
Number of subjects per Galactomannan titer level with global response for all subjects (with or without renal impairment). The galactomann assay is an immunological blood serum test used to diagnose invasive aspergillosis and to monitor disease progression. Global response is a composite of clinical and radiological findings summarized as Complete Response: resolution of all clinical signs and symptoms; Partial Response: clinical improvement; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.
Time frame: Up to Week 6
Voriconazole Trough Levels With Intravenous and Oral Dosing
Voriconazole trough plasma concentrations measured as nanograms per milliliter (ng/mL).
Time frame: Week 1 through Week 6
| Milestone | Anidulalfungin and Voriconazole |
|---|---|
| Started | 6 |
| Completed | 5 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.
| participants | Anidulalfungin and Voriconazole |
|---|---|
| Failure (No response) | 1 |
| Partial response | 3 |
| Stable response | 0 |
| Complete response | 2 |
Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.
No measurements were reported for this outcome.
Number of subects with documented mortality (death).
| participants | Anidulalfungin and Voriconazole |
|---|---|
| Summary of Mortality | 1 |
Number of subjects per Galactomannan titer level with global response for all subjects (with or without renal impairment). The galactomann assay is an immunological blood serum test used to diagnose invasive aspergillosis and to monitor disease progression. Global response is a composite of clinical and radiological findings summarized as Complete Response: resolution of all clinical signs and symptoms; Partial Response: clinical improvement; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.
No measurements were reported for this outcome.
Voriconazole trough plasma concentrations measured as nanograms per milliliter (ng/mL).
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anidulalfungin and Voriconazole | — | 4/6 (66.7%) | 6/6 (100%) |
| Event | Anidulalfungin and Voriconazole |
|---|---|
| Disease progressionGeneral disorders | 1/6 |
| Renal failure acuteRenal and urinary disorders | 1/6 |
| HydropneumothoraxRespiratory, thoracic and mediastinal disorders | 1/6 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/6 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/6 |
| Event | Anidulalfungin and Voriconazole |
|---|---|
| Cardiac failure congestiveCardiac disorders | 2/6 |
| VomitingGastrointestinal disorders | 2/6 |
| AnaemiaBlood and lymphatic system disorders | 1/6 |
| LeukocytosisBlood and lymphatic system disorders | 1/6 |
| DiarrhoeaGastrointestinal disorders | 1/6 |
| HaematemesisGastrointestinal disorders | 1/6 |
| NauseaGastrointestinal disorders | 1/6 |
| PyrexiaGeneral disorders | 1/6 |
| Oropharyngeal candidiasisInfections and infestations | 1/6 |
| Blood glucose increasedInvestigations | 1/6 |
| Age, Customized(participants) | Anidulalfungin and Voriconazole |
|---|---|
| Between 57 and 83 years | 6 |
| Sex: Female, Male(Participants) | Anidulalfungin and Voriconazole |
|---|---|
| Female | 1 |
| Male | 5 |
The record gives a start of Aug 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Voriconazole · Anidulafungin